No quarterly revenue total was found in ALX ONCOLOGY HOLDINGS INC's SEC filings.
Alx Oncology Holdings Inc (ALXO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.1 million. As of Jun 30, 2026 it held $153.4 million in cash and investments and $11.5 million in total debt.
Revenue
—
Net income
$-17.97M
+30.7% vs year-ago quarter
Operating cash flow
$-16.06M
+31.4% vs year-ago quarter
Free cash flow
$-16.07M
+31.5% vs year-ago quarter
EPS
$-0.13
+73.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
138.28M
+158.2% vs year-ago quarter
Net cash
$141.84M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALXO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810182
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$18.0M | -$19.0M | -$23.0M | -$22.5M | -$26.6M |
| Net income | -$18.0M | -$17.9M | -$22.8M | -$22.1M | -$25.9M |
| Diluted EPS | -$0.13 | -$0.17 | -$0.42 | -$0.41 | -$0.49 |
| Operating cash flow | -$16.1M | -$18.6M | -$19.0M | -$17.1M | -$23.4M |
| Free cash flow | -$16.1M | -$18.7M | -$19.0M | -$17.1M | -$23.5M |
| Total assets | $160.8M | $178.3M | $59.0M | $82.7M | $95.3M |
| Total liabilities | $24.6M | $27.0M | $33.1M | $37.9M | $30.9M |
| Stockholders' equity | $136.2M | $151.3M | $26.0M | $44.8M | $64.4M |
| Cash and investments | $153.4M | $169.1M | $48.3M | $66.5M | $83.5M |
| Total debt | $11.5M | $13.4M | $15.2M | $16.1M | $16.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 15, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
All 421 Alx Oncology Holdings Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.